Study Completed

Biological availability

Bayer Identifier:

19604

ClinicalTrials.gov Identifier:

NCT03353857

EudraCT Number:

2017-002792-26

EU CT Number:

Not Available

Drug-drug interaction between rifampicin and progestins/ethinylestradiol and midazolam

Trial purpose

Quantify the effect of a probe CYP3A4 inducer (Rifampicin) on the pharmacokinetics of levonorgestrel, norethindrone, desogestrel, dienogest, drospirenone,estradiol and midazolam

Key Participants Requirements

Sex

Female

Age

45 - 70 Years

Inclusion Criteria
- Healthy female subject based on a complete medical history, physical examination, ECG, and clinical laboratory tests
- Age: 45 to 70 years (inclusive) at the first screening visit
- Minimum body weight 50 kg with Body mass index (BMI) above or equal to 18.5 kg/m², and below or equal to 30 kg/m² at the first screening visit
- Postmenopausal state, revealed indicated by either:
-- medical history, if applicable (natural menopause at least 12 months prior to first study drug administration, for women younger than 60 years confirmed by follicle stimulating hormone (FSH) >40 IU/L AND estradiol ≤ 20 pg/mL; or
-- surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration)
Exclusion Criteria
- Relevant diseases within the last 4 weeks prior to the first study drug administration, i.e. any disease requiring treatment by a health-care provider
- Febrile illness within 1 week before the first study drug administration
- Known severe allergies, non-allergic drug reactions, or multiple drug allergies
- Presence or history of thrombosis, thrombophlebitis, thromboembolic diseases of veins and/or arteries, e.g. deep vein thrombosis, stroke, myocardial infarction, pulmonary embolism, transient ischemic attack, angina pectoris
- Presence or history of conditions that increase the risk of thromboembolic diseases, e.g. disturbances of the coagulation system, thromboembolic diseases in close relatives at age ≤50 years], valvular heart disease, atrial fibrillation, cardiac dysfunction)
- Presence, history, or suspected presence of malignant tumors or tumors of the liver and pituitary
- Presence or history of liver disease e.g. disturbances of the bilirubin excretion (Dubin-Johnson and Rotor syndromes), cholecystectomy ; cholestasis, idiopathic icterus or pruritus during a previous pregnancy or estrogen-progestogen treatment
- Relevant kidney diseases or renal injury associated with multisystem diseases/disorders, e.g. glomerulonephritis systemic lupus erythematous, diabetic nephropathy. A history of a single episode of uncomplicated nephrolithiasis does not prevent participation
- Known metabolic disorder, e.g. diabetes mellitus, severe hypertriglyceridemia
- Migraine with neurologic symptoms
- Clinically significant depression, current or in the last year
- Known current thyroid disorders which require treatment. Subjects with an euthyroid struma who do not need any treatment can participate.
- Chronic respiratory insufficiency
- History of porphyria
- Contraindications for midazolam, e.g. myasthenia gravis, and sleep apnea

Trial summary

Enrollment Goal

Trial Dates

November 2017 - February 2019

Phase

Phase 1

Could I Receive a placebo

Products

BAY1902607

Accepts Healthy Volunteer

Yes

Where to participate

Status	Institution	Location
Completed	CRS Clinical-Research-Services Mönchengladbach GmbH	Mönchengladbach, 41061, Germany
Completed	CRS Clinical-Research-Services Mannheim GmbH	Mannheim, 68167, Germany

Primary Outcome

Area under the plasma concentration time curve from zero to infinity (AUC) of levonorgestrel in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Maximum plasma concentration (Cmax) of levonorgestrel in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Area under the plasma concentration time curve from zero to infinity (AUC) of norethindrone in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Maximum plasma concentration (Cmax) of norethindrone in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Area under the plasma concentration time curve from zero to infinity (AUC) of etonogestrel in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Maximum plasma concentration (Cmax) of etonogestrel in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Area under the plasma concentration time curve from zero to infinity (AUC) of dienogest in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Maximum plasma concentration (Cmax) of dienogest in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Area under the plasma concentration time curve from zero to infinity (AUC) of drospirenone (+EE) in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Maximum plasma concentration (Cmax) of drospirenone (+EE) in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Area under the plasma concentration time curve from zero to infinity (AUC) of ethinylestradiol (+DRSP) in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Maximum plasma concentration (Cmax) of ethinylestradiol (+DRSP) in the presence of MDZ (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Area under the plasma concentration time curve from zero to infinity (AUC) of midazolam in combination with the hormonal contraceptive only (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3
Maximum plasma concentration (Cmax) of midazolam in combination with the hormonal contraceptive only (without RIF) and in combination with 10 mg/d and 600 mg/d RIF
Time Frame:
Over 7 days in Period 1 (no RIF) and 4 days in treatment Periods 2 and 3

Trial design

Open-label, randomized, fixed sequence cross-over study with five parallel treatment arms and three treatment periods to quantify the drug-drug interactions of two rifampicin dose strengths on four progestins and a fixed progestin-ethinylestradiol combination compared with midazolam in healthy post-menopausal women

Trial Type

Interventional

Intervention Type

Drug

Trial Purpose

Other

Allocation

Randomized

Blinding

N/A

Assignment

Parallel Assignment

Trial Arms

Additional Information

Click here to find information about studies related to Bayer Healthcare products conducted in Europe.Click here to find results for studies related to Bayer Healthcare products.